ABSTRACT The gonadotropin receptors LH receptor and FSH receptor play a central role in governing reproductive competency/fertility. Gonadotropin hormone analogs have been used clinically for decades in assisted reproductive therapies and in the treatment of various infertility disorders. Though these treatments are effective, the clinical protocols demand multiple injections, and the hormone preparations can lack uniformity and stability. The past two decades have seen a drive to develop chimeric and modified peptide analogs with more desirable pharmacokinetic profiles, with some displaying clinical efficacy, such as corifollitropin alfa, which is now in clinical use. More recently, low-molecular-weight, orally active molecules with activity at gonadotropin receptors have been developed. Some have excellent characteristics in animals and in human studies but have not reached the market-largely as a result of acquisitions by large pharma. Nonetheless, such molecules have the potential to mitigate risks currently associated with gonadotropin-based fertility treatments, such as ovarian hyperstimulation syndrome and the demands of injection-based therapies. There is also scope for novel use beyond the current remit of gonadotropin analogs in fertility treatments, including application as novel contraceptives; in the treatment of polycystic ovary syndrome; in the restoration of function to inactivating mutations of gonadotropin receptors; in the treatment of ovarian and prostate cancers; and in the prevention of bone loss and weight gain in postmenopausal women. Here we review the properties and clinical application of current gonadotropin preparations and their analogs, as well as the development of novel orally active, small-molecule nonpeptide analogs. (Endocrine Reviews 39: 911 -937, 2018) 
anterior pituitary stimulate the production and secretion of the gonadotropin hormones LH and FSH, which are released into the general circulation to stimulate gonadal steroidogenesis, peptide hormone secretion (inhibin and activin), and gametogenesis. Gonadal steroids and peptide hormones then feed back in negative and positive modalities at the hypothalamus and/or pituitary (, ).
The actions of gonadotropins in the HPG axis
The gonadotropin glycoproteins exert their effects on the HPG axis through interaction with and activation of their cognate receptors, the LH receptor (LHCGR/ LHR) and FSH receptor (FSHR). Whereas a number of studies have documented the presence of LHR and FSHR in extragonadal tissues (, ), physiologically, their primary site of activity is the gonads. FSHR activation stimulates follicular development in females and the initiation of spermatogenesis in males whereas LHR stimulation is responsible for steroidogenesis and follicular/gamete maturation, as well as the induction of ovulation in females. LH regulates expression of steroidogenic enzymes and the subsequent production of androgens within the interstitial Leydig and thecal cells of the testes and ovaries, respectively. Steroidogenesis is also dependent on the activity of FSH in testicular Sertoli cells and the granulosa cells of the ovaries, supporting gonadal development and facilitating the conversion of androgen to estrogen via the enzyme aromatase. Activation of FSHR additionally results in the production of the TGF-b family members activin and inhibin, which positively and negatively feed back to the pituitary and hypothalamus to regulate FSH production/activity ().
The gonadotropin-secretion profiles are also sexually dimorphic, differing dramatically between males and females. Whereas LH pulse frequency remains constant in males, it varies over the female menstrual cycle with low-frequency pulses during the luteal phase of the cycle and higher-frequency pulses in the follicular phase. FSH pulsatility is less discernible, as unlike LH, FSH is not stored in secretion granules and has a longer half-life in the circulation. In females, FSH activity in the late-luteal/early-follicular phases of the cycle is responsible for recruitment of five to seven Graafian follicles into the menstrual cycle and drives follicular development. Estradiol, produced by the developing follicle, feeds back negatively to the hypothalamus, resulting in suppressed LH secretion. Through poorly defined mechanisms, an estradiol threshold is reached, at which point estradiol switches to positive feedback, resulting in a midcycle increase in LH pulse frequency and surge of LH, which are responsible for initiating ovulation and luteinization of the ruptured follicle. The luteinized follicle, or corpus luteum, subsequently produces progesterone that prepares the uterine endometrium for implantation. Progesterone also feeds back negatively at the hypothalamus, suppressing LH secretion, resulting in atrophy of the corpus luteum should implantation not occur.
The importance of both glycoprotein hormones and their receptors in gonadal function is highlighted by the pathophysiologies attributed to inactivating (or constitutively activating) mutations that affect the LH/ LHR and FSH/FSHR signaling modalities. Loss of functional LH and FSH in males and females can result in impaired fertility/infertility phenotypes and in the case of LH, a lack of pubertal development (, ). The severity of the phenotype attributed to mutations in the LHR correlates with the degree of receptor inactivation and a resultant spectrum of phenotypes from ESSENTIAL POINTS · Urinary gonadotropin analogs have been used clinically for decades in assisted reproductive therapies and in the treatment of various infertility disorders · Issues with the gonadotropin peptide hormones include clinical protocols requiring multiple injections, nonuniformity of preparations, protein stability, and increased risk of ovarian hyperstimulation syndrome · More recently, recombinant gonadotropin preparations have been favored as a result of their improved purity and batchto-batch consistency · Gonadotropin hormones with differing half-lives and oral bioavailability may mitigate the need for repeated injections and reduce side-effects associated with current treatment regimens · Several peptide analogs have been developed, one of which, an FSH analog with an increased half-life (corifollitropin alfa), has entered the clinic · A spectrum of orally available, low-molecular-weight gonadotropin analogs (agonists and antagonists) has been in development, but none is yet commercially available, and many development programs have been terminated as a result of pharmaceutical company mergers or acquisitions · In addition to use in assisted reproductive therapies, gonadotropin analogs may have potential application as contraceptives and in the treatment of polycystic ovary syndrome and ovarian and prostate cancers and prevention of bone loss and weight gain in postmenopausal women pseudohermaphroditism and hypogonadism through to the less severe micropenis and oligomenorrhea (). Interestingly, loss of FSH/FSHR signaling in females results in infertility, in contrast to males, where homozygous-inactivating FSH/FSHR mutations appear to result in a qualitative and quantitative reduction in spermatogenesis without rendering the patient completely infertile, implying a level of redundancy in FSHR signaling with regard to male fertility (-). These findings appear to be supported by an FSH-deficient mouse model in which female mice had folliculogenesis defects and were infertile, whereas males displayed impaired testes development but remained fertile ().
Regulation of gonadotropin secretion
In both male and female systems, the processes regulating the production and secretion of the gonadotropins are complex and represent an intricate relationship among hormonal and steroidal production, secretion, and feedback (, , ). As mentioned previously, the secretion of LH and FSH from gonadotropes is sexually dimorphic, and in females, the circulating hormone levels fluctuate dramatically throughout the menstrual cycle. This differential regulation is the result of a complex interplay of a multitude of physiological inputs, including metabolic status, stress, and inflammatory cues, in addition to steroidal and peptide feedback mechanisms into the hypothalamus and pituitary (-). GnRH is released in a pulsatile manner (, ), and it has long been known that each pulse of GnRH results in a concomitant pulse of LH transcription and secretion (). Pulses of FSH can also be detected following GnRH stimulation of gonadotropes, but in contrast to LH, this regulation appears to be at the level of FSH b-subunit transcription, as FSH secretion appears to be largely constitutive (-). The issue of how GnRH differentially regulates the contrasting profiles of the two gonadotropins across the menstrual cycle was resolved following the discovery that LH and FSH transcription was differentially affected by GnRH pulse frequency (, ). High-frequency pulses of GnRH appear to favor LH, whereas low-frequency pulses promote FSH synthesis.
Gonadotropin hormone structure and function
The pituitary gonadotropin hormones LH and FSH, as well as the placentally derived LH paralog hCG, are all large, heterodimeric glycoproteins that consist of aand b-subunits. Along with the pituitary-derived TSH, this group of hormones is termed the glycoprotein hormones. The glycoprotein hormone heterodimers are composed of a -amino acid (aa) a-subunit encoded by a single gene common to all three hormones () and a hormone-specific b-subunit (LH:  aa; hCG:  aa; FSH:  aa; and TSH:  aa). LH and hCG differ only by a C-terminal, -aa peptide [carboxy-terminal peptide (CTP)] extension in hCG, and both activate the LHR with similar potencies in vitro (). However, the CTP confers an increased halflife to hCG. The a-and b-subunit heterodimers form through noncovalent interactions, whereas the intrasubunit tertiary structure is largely governed by disulfide bonds (), with the a-and b-subunits containing  and  cysteine residues, respectively (). The resolution of the crystal structure of hCG demonstrated that the a-and b-subunit interaction is stabilized by a cysteine loop of the b-subunit that encircles loop two of the a-subunit in a manner resembling a seatbelt (). Two disulfide bonds, conserved in all of the human glycoprotein hormones, are responsible for the "locking" of the seatbelt around the a-subunit (). Whereas the a-and b-subunits both contribute to receptor binding, molecular modeling and the use of chimeric proteins have identified a "determinant" loop in the b-subunit (aa  to ) that confers receptor binding specificity (-).
The mature gonadotropin hormones are heavily glycosylated. The common a-subunit has two Nlinked glycosylation sites (N and N), with the hormone-specific b-subunits containing either one (LH: N) or two (FSH: N and N and hCG: N and N) N-linked sites (). The hCG CTP extension also contains an additional four O-linked glycosylation sites. Chemical and enzymatic removal of the oligosaccharide moieties or removal of a-and b-subunit glycosylation sites via site-directed mutagenesis has revealed a number of important roles for these residues. Whereas the function of O-linked glycosylation of the CTP appears to be predominantly related to reduced clearance rates and increased half-life and biological activity (, ), N-linked glycosylation appears to be more complex. Evidence for roles in determining clearance rates has been reported, with a number of studies suggesting that the number of terminal sialic acid or sulfonated N-acetylgalactosamine residues present on the glycan determines the rate of hepatic clearance, with increased sialylation reflecting a longer half-life and increased sulfonation resulting in faster clearance (-). Roles in receptor activation have also been demonstrated, as deletion of the N-linked glycosylation residues reduces biological activity with only a marginal effect on receptor binding (, -). Mutagenesis studies have demonstrated that removal of the a-subunit N site affects bioactivity (, -), whereas loss of b-subunit glycosylation sites may exacerbate the loss of bioactivity induced by loss of N (). Roles of glycosylation in subunit synthesis and heterodimer secretion have also been indicated (, , , ).
The nature, as well as the presence, of the glycosylation also appears to affect gonadotropin bioactivity. Charge variants (due to differential glycosylation) and variants with the same net charge but different glycosylation status can affect biological activity. For example, basic isoforms (reduced sialylation) display higher binding affinities and biopotencies in heterologous cell-assay systems than the acidic isoforms, and some of the most basic isoforms (pH . .) have antagonistic activity (-). Intriguingly, antagonism of GnRHR has been shown to result in elaboration of a greater proportion of these basic forms of FSH, which act as antagonists (). Differentially glycosylated FSH isoforms appear to have physiological relevance, as during puberty and the transition from early-to-late follicular phase, there is a progressive increase in the ratio of basic-to-acidic isoforms, and this appears to be tightly controlled by estradiol (). Moreover, different FSH glycoforms are apparently capable of activating different FSHR signaling modalities, with a number of studies documenting differential recruitment of downstream signaling components (Gas, Gai, and b-arrestin) and differences in cAMP release, estradiol production, tissue-type plasminogen activator, cytochrome P aromatase, and a-inhibin subunit expression (, , , , , ).
Gonadotropin receptor structure and function
The gonadotropin receptors are members of the glycoprotein-hormone receptor subfamily of the rhodopsin-like class of G protein-coupled receptors (GPCRs) and have the prototypical seven transmembrane (TM) domain architecture of GPCRs. The transmembrane (TM) domains are linked by three intracellular loops and three extracellular loops (ECLs) with an intracellular C-terminus and an extracellular N-terminal domain (ECD). Ligand activation of GPCRs promotes association with intracellular GDPbound heterotrimeric G proteins. The activated receptor acts as a guanine-nucleotide exchange factor, promoting GTP displacement of GDP on the G protein Ga-subunit. This exchange promotes dissociation of the heterotrimeric G protein into a monomeric GTP-Ga-subunit and a heterodimeric Gbg-subunit. The dissociated subunits then activate intracellular signaling pathways. In the case of the gonadotropin receptors, the activated Ga-subunits are responsible for activation of the enzyme adenylyl cyclase, resulting in the production of the second messenger cAMP. Whereas cAMP is acknowledged as the "classical" intracellular signal, generated following gonadotropin receptor activation, inositol phosphate/ Ca + , MAPK (ERK and p), and phosphatidylinositol -kinase/AKT signaling modalities have also been reported (-). Moreover, the phenomena of "biased agonism," whereby specific ligands preferentially recruit certain signaling pathways, which is well described for other GPCRs, has only recently emerged for gonadotropin receptors, predominantly through the use of small molecule agonists (discussed later).
The glycoprotein hormone receptors are unique among GPCRs in having very large ECDs (. aa), consisting of a cysteine-rich domain, followed by several leucine-rich repeats (LRRs) (, ). The glycoprotein hormones interact with this large Nterminal domain (). The LRRs have been demonstrated to form a slightly curved solenoid, with the hormone binding to the curved inner surface. The receptor wraps around the central portion of the hormone through both hormone subunits and occurs over a large interface, described as a "hand clasp." This interaction is mediated via a number of charge interactions, salt bridges, and aromatic ring-stacking interactions (, ). A region proximal to the ECL/ TM domains, which is designated the "hinge region," is known to play an important role in the activation of the receptor following hormone binding. The mechanism through which activation occurs is not fully known, but resolution of the crystal structure of FSH, in complex with the entire ectodomain of FSHR (including the hinge region), suggested a possible mechanism via a second hormone-interaction site at a sulfated tyrosine in the C-terminus of the hinge (Y) (, ). This interaction is proposed to lift the hinge region, leading to activation of the receptor through the unmasking of an intramolecular agonist sequence juxtaposed to the ECL/TM (Fig. ) (, ). This is in contrast to previous hypothesized mechanisms, whereby the hormone itself was proposed to make direct contact with the ECLs and juxtamembrane regions of the TM domains to induce receptor activation ().
Gonadotropin Analogs in Clinical Use
The importance of the pituitary in reproductive physiology was determined in the early th century. The pioneering work of Bernhard Zondek in the s and s linked the secretion of gonadotropins (then termed prolan A and B) from the pituitary to follicular growth and steroidogenesis (), paving the way for the application of gonadotropins in clinical medicine. To this end, several gonadotropin analogs/preparations have been developed for clinical use. Indeed, urinary hCG (pregnyl) has been available for therapeutic application from as early as  ().
Purified/recombinant gonadotropin preparations Initial preparations of gonadotropins for clinical use were derived from pituitary extracts; however, this practice was discontinued, as the supply of human pituitaries could not meet the demand and also, the recognition of a possible link to the transmission of prion disease (). Endogenous gonadotropins are now extracted from the urine of pregnant or postmenopausal women, including chorionic gonadotropin (hCG), urofollitropin (FSH), and menotropin/ human menopausal gonadotropin (hMG; which contains both FSH and LH). These preparations continue to be widely used, despite issues regarding a lack of regulatory control, batch-to-batch variation, and limited source availability (Table ) . However, continued improvement of purification methodologies has enabled the production of highly purified preparations.
The advent of the molecular era resulted in the availability of recombinant gonadotropins [follitropin alfa/beta/delta (FSH), lutropin alfa (LH), and choriogonadotropin alfa (hCG) ( Table ) ], allowing for the production of highly pure preparations, batch-tobatch consistency, and flexible dosing regimens and protocols, resulting in more effective personalizedtreatment regimens. Responses to urinary and recombinant gonadotropin preparations are similar (), and because of the limited evidence of benefit in assisted reproduction and associated cost implications, recombinant gonadotropins have only partly replaced urinary hCG/hMG in fertility treatments.
Different sources and preparations of gonadotropins (both recombinant and human derived) can vary in their receptor binding and signal-transduction capabilities, and this is related to their glycosylation status. For example, differences in the clinical activity of different preparations have been attributed to carbohydrate content, which varies depending on the methods used for their production and/or purification ().
Gonadotropin chimeras (corifollitropin alfa)
In addition to enabling the production of large quantities of native heterodimer, recombinant technologies have been used to generate chimeric gonadotropins, such as corifollitropin alfa (Org ; Table  and Table ) , an FSH heterodimeric protein in which the CTP of hCGb is fused to the C-terminus of the b-subunit of FSH to increase the biological halflife. The chimeric b-subunit (FSH-CTP) does not affect biosynthesis or secretion of the heterodimer in cells used for production of recombinant protein.
Moreover, FSH binding to rat testes membrane preparations and steroidogenic activity in granulosa cells were retained (). Furthermore, the in vivo potency (measured as increased ovarian weight and granulosa cell aromatase activity following administration of corifollitropin alfa to immature, estrogenprimed rats) and biological half-life of corifollitropin alfa were significantly increased compared with wildtype FSH, whereas no LHR binding was detected (). A phase I nonblind multicenter study followed, in which hypogonadotropic hypogonadal (HH) men were injected subcutaneously (SC), four times with  mg corifollitropin alfa at -week intervals. No serious adverse effects or generation of antibodies against the protein were reported, and the elimination half-life for corifollitropin alfa of  hours was considerably longer than that of follitropin beta (Puregon;  to  hours) (). In a subsequent study, in healthy females of reproductive age, a high dose of oral contraceptive (Lyndiol) was administered to suppress endogenous gonadotropin secretion, followed by , , , or  mg SC injection of FSH-CTP. As in the HH males, no antibodies against the compound were detected, and increases in serum inhibin B concentration and follicular growth (both number and size of follicles) were observed in a dosedependent manner. The elimination half-life was approximately twofold slower than follitropin alfa (Gonal-F). Interestingly, the time to reach maximum serum concentration was also slower than that described for recombinant FSH, possibly as a result of slower absorption (, -).
In , pregnancy and live birth after use of corifollitropin alfa in an ovarian hyperstimulation protocol were reported. In this phase II trial, a -yearold woman, who had primary infertility and two failed in vitro fertilization cycles, was injected with  mg corifollitropin alfa SC. After  days, daily injections of follitropin beta (Puregon;  IU), in combination with a GnRH antagonist, were administered for  days, after which final oocyte maturation and ovulation were induced by administration of , IU hCG. Of the  oocytes that were retrieved,  were fertilized via intracytoplasmic sperm injection, and two embryos were implanted, resulting in one live birth (). Subsequent studies showed that pregnancy rates in a cohort of  patients undergoing ovarian stimulation with a GnRH antagonist protocol were almost indistinguishable between women treated with one SC injection of corifollitropin alfa ( mg) or  daily injections of recombinant FSH ( IU). Additional efficacy and dosing studies have demonstrated that corifollitropin alfa injections have favorable pharmacokinetic profiles and comparable, or moderately improved, pharmacodynamic responses compared with recombinant FSH. This suggests that a single weekly injection of corifollitropin alfa could replace daily injections of recombinant FSH during ovarian hyperstimulation protocols (-).
As a result of the extended duration of action of corifollitropin alfa and the inability to control dose after administration, there is a risk that ovarian hyperstimulation syndrome (OHSS; the development of multiple luteinized ovarian cysts, leading to ovarian enlargement and development of vascular hyperpermeability) may be exacerbated in patients treated with this long-acting gonadotropin analog. However, adverse events, including OHSS, in two additional double-blind randomized trials in healthy women (Engage) and women of lower body weight (Ensure). were of similar frequency to that observed in patients treated with recombinant FSH (, ). A further phase III trial (Trust) that studied the effects of repeated administration of  mg corifollitropin alfa in up to three controlled ovarian hyperstimulation cycles concluded that there was no immunogenicity or drug-related hypersensitivity (). Although no increased incidence of OHSS was reported in the Engage, Ensure, and Trust trials (, , ), women with polycystic ovarian syndrome (PCOS) or with a history of OHSS had been excluded from these trial cohorts. Therefore, the suitability of corifollitropin alfa for higher-risk patients remains to be determined.
Following phase III trials, in early , corifollitropin alfa (under the trade name of Elonva; Table ) was approved for use in the European Union in women undergoing controlled ovarian hyperstimulation with a GnRH antagonist-assisted reproduction protocol who have no history of OHSS or PCOS.
Therapeutic Applications of Gonadotropin Analogs
Gonadotropin therapy in men The differential sites of action of LH and FSH at Leydig and Sertoli cells, respectively, underpin their clinical use in the support of steroidogenesis and of spermatogenesis in men suffering from HH. hCG provides a very convenient form of LH-like activity and is generally administered at doses of  to  IU, twice per week, with the opportunity to titrate the dose, depending on the serum testosterone level achieved. These doses are, however, far higher than those needed to normalize intratesticular testosterone concentrations in men with induced experimental gonadotropin deficiency. Thus, low doses of hCG ( IU) on alternate days can normalize serum testosterone levels (). FSH (either urinary or recombinant) is conventionally administered in addition to hCG. However, in adult men with previously normal spermatogenesis who have subsequently become gonadotropin deficient, for example, as a result of pituitary surgery, hCG alone can often restore spermatogenesis. On the other hand, men who have never achieved spermatogenesis also require FSH.
Whereas overall, the prospects for spermatogenesis are high (~%) in men with either prepubertal-or postpubertal-onset HH, it is more successful in men with postpubertal onset (% vs %), with higher sperm concentrations also being achieved (. vs . million/ml). Prior androgen therapy was believed to be associated with a slower response to gonadotropin therapy (), but a meta-analysis of  studies revealed no association (). However, testicular volume is a positive prognostic indicator of response, as is previous treatment with gonadotropins, whereas cryptorchidism is an important negative predictor. The longacting version of FSH, corifollitropin alfa, has also been used in hypogonadotropic men, and in a small open label trial, spermatogenesis was established in % of men who remained azoospermic after treatment with hCG alone (). Administration of this long-acting analog, once every  weeks, greatly reduces the treatment burden, and on the basis of this limited evidence, it appears similarly efficacious to FSH.
It is important to recognize that quantitatively, normal spermatogenesis is often not achieved in these cases and additionally, that significant duration of treatment may be required before a detectable sperm concentration is achieved. Thus, in one large study, the median time to achieve the first detectable sperm was . months (% confidence interval, . to .), with conception achieved after a median of . months (. to .). The median sperm concentration at natural conception was . million/ml, with the lowest sperm concentration at conception at . million/ml (). Thus, men should be advised that treatment may be required for at least  years. Moreover, the age of the female partner can be an important determinant of successful pregnancy. A commonly used protocol is initiation of androgen production with the use of hCG alone for~ months and addition of FSH at that stage unless sperm are already detectable in the ejaculate. The main advantages of this approach are to save on the cost of FSH and also, to reduce the frequency of injections, from the five required for administration of both gonadotropins, to two per week for just hCG. It is possible that administration of both gonadotropins from the start may result in more rapid onset of spermatogenesis, but robust data supporting this are absent. Additionally, pretreatment with FSH alone has been proposed, and in men with congenital HH without prior gonadotropin treatment, a small trial indicated that this approach could be successful (). FSH treatment of  months before GnRH (thus, inducing both LH and FSH secretion) resulted in normalization of serum inhibin B, increased testicular volume, proliferation of Sertoli cells, and spermatogonia (at biopsy) and the presence of sperm in the ejaculate in all men.
In adolescent boys with delayed puberty as a result of HH, the standard approach of using testosterone administration results in growth, virilization, and psychosexual maturation without testicular development or induction of fertility. Therefore, there is a possibility that subsequent fertility may be improved if gonadotropins are instead used for this purpose. A recent multicenter study of  patients addressed this. The administration of hCG with recombinant FSH in boys and adolescents with HH resulted in the presence of sperm in the ejaculate in over % of subjects, whether they had previously been treated with testosterone and with similar final testicular volumes (). Thus, in keeping with a meta-analysis in adult men (), previous testosterone therapy was not found to be disadvantageous, although a possible advantage of gonadotropin-induced puberty would be that spermatogenesis can subsequently be more rapidly induced in men previously treated with gonadotropins when fertility is desired.
Gonadotropin therapy in women
Gonadotropins can be used to induce ovulation, either to stimulate mono-ovulation (for support of natural conception or intrauterine insemination) or in ARTs, where a multifollicular response is desired (conventionally called "controlled superovulation," albeit with less control than that term indicates).
Mono-ovulation
The ability of exogenous gonadotropin preparations to induce ovulation in both hypogonadotropic women and in those with normogonadotropic anovulation (generally as a result of PCOS) has been recognized, as such preparations became available in the late s (). This approach excludes the normal, negativefeedback pathways that fine tune LH and FSH secretion from the pituitary to ensure selection and ovulation of just one follicle from many antral follicles present in the ovary at the start of the menstrual cycle. To minimize multifollicular development and the resultant risk of a multiple pregnancy, the current regimen of choice is the low-dose step-up protocol, wherein low initial doses of gonadotropins (generally  to  IU FSH) are increased only at infrequent intervals, initially after  weeks and thereafter, at -week intervals (). A step-down protocol, aiming to mimic more closely physiologic changes in FSH, has also been developed with good success rates () but has not been widely adopted.
Recombinant/urinary FSH is generally used for women with PCOS (as they are not LH deficient) who are resistant to antiestrogen therapy or who have become ovulatory with antiestrogen but have not conceived. Recent meta-analyses and guidelines confirm the value of gonadotropins as the appropriate second-line therapy in women with PCOS wishing to become pregnant (-), and whereas it may offer a more rapid time to pregnancy than with clomifene (), the complexity (and expense) of treatment generally precludes this. With this approach, mono-ovulation can be induced in over % of cycles, with a live birth rate of~% per cycle and a cumulative live birth rate of~%. This can be achieved with a very low multiple live-birth rate of .% but only by application of rigorous cancellation criteria in the event of a multifollicular response ().
In severely hypogonadotropic women, preparations containing LH activity must be used. In such patients, induction of ovulation is more difficult (with a higher cycle cancellation rate reflecting a higher multifollicular response), and a lower pregnancy rate is achieved. Therefore, such women are ideally treated with pulsatile GnRH (whereby the involvement of physiological feedback pathways contribute to high rates of mono-ovulation), but this is of very limited availability.
Superovulation
The use of high doses of FSH for controlled superovulation before assisted reproduction has now resulted in several million live births around the world. There are several protocols described and well established, and dosage is often guided by measurement of antral follicle count or of serum antiMüllerian hormone, which can identify women at risk for excessive or low response, with dose adaptation or additional counseling as appropriate (, ). This continues to be an evolving field reflecting limited evidence comparing key aspects of treatment, such as the optimal dose of FSH to optimize the response (, ). It does, however, carry some risk, particularly of OHSS and of multiple pregnancy if more than one embryo is subsequently transferred (, ). The risk of OHSS has been dramatically reduced in recent years by using GnRH antagonist-based protocols to suppress endogenous gonadotropin secretion rather than GnRH agonists that cause an initial "flare" in GnRHR activity (, ). Whereas GnRH antagonist protocols may be associated with a slightly reduced live-birth rate, possibly as a result of as-yet underoptimized luteal replacement, this seems not to be the case in women with PCOS, and it has been suggested as standard therapy for that group (). GnRH antagonist cycles do not, however, completely prevent the risk of the development of OHSS, and other established therapies include cycle cancellation, the use of a GnRH agonist to trigger oocyte maturation, and a freeze-all strategy, with the latter often referred to as "cycle segmentation" ().
The risks of multiple pregnancies have been reduced in recent years by using elective single-embryo transfer (). Although this results in reduced livebirth rates per cycle, cumulative rates over multiple cycles are maintained ().
Novel approaches to assisted reproduction using gonadotropins have, in large part, been stimulated by the need for protocols that do not require any delay before their commencement, generally known as random start protocols, and the double-stimulation approach, which allows two stimulation cycles to be administered with only a very brief interval in between. Both of these approaches are of particular benefit in patients newly diagnosed with cancer, where time is of the essence, and normal endometrial development is irrelevant, as all oocytes or resulting embryos will be cryopreserved.
The initial approach to more rapid-onset FSH administration involved luteolysis with the use of a GnRH antagonist (), but it subsequently became clear that FSH administration could be started at almost any stage of the cycle, other than in the immediate periovulatory period. This approach gives comparable oocyte number and apparent developmental competence to those obtained after routine ovarian stimulation, and whereas data on pregnancy rate remain limited as a result of the nature of the circumstances of these patients, they appear acceptable (). The addition of the antiestrogen tamoxifen and more recently, the aromatase inhibitor letrozole to such regimens in women with hormonedependent cancer to reduce estradiol production has also been used as a further level of refinement under those specific circumstances (-), although this use is "off label." Double stimulation is an alternative approach, wherein gonadotropin administration is restarted a few days after a GnRH agonist trigger (). This approach can substantially increase the number of oocytes obtained, and indeed, it may be the case that more oocytes are obtained during the second phase of stimulation than in the first, thus more than doubling the oocyte yield (). This approach can also potentially reduce the cancellation rate, particularly in women with a poor ovarian response or who are older, and the limited data that are available indicate that the developmental potential of embryos derived from each of the two stimulations is comparable (, ).
Development of Gonadotropin Analogs

Polypeptide gonadotropin analogs
Single-chain and dual-activity gonadotropins As discussed, gonadotropin preparations (both endogenous and recombinant) are used therapeutically in a number of clinical settings. The duration of treatment (in some cases, months) has necessitated the development of long-acting polypeptide analogs to mitigate the need for multiple injections for improved patient convenience. Corifollitropin alfa is one example of a long-acting FSH analog, although a major drawback is that the corifollitropin alfa is a heterodimer. The stability of corifollitropin alfa and heterodimeric urinary gonadotropins is an issue during purification, shipping, and storage. In an attempt to overcome these issues, Sugahara et al. () synthesized a single-chain hCG analog in which the hCGb-subunit was fused to the N-terminus of the gonadotropin a-subunit (hCGba; Table  ). The in vivo biopotency of this single-chain analog was shown to be greater than the heterodimer, as measured in a rat ovulatory assay (). The enhanced biological activity was suggested to be a result of improved pharmacokinetics, as the single-chain analog is not subject to subunit dissociation (). Interestingly, the single-chain analog with the a-subunit oriented at the N-terminus of the b-subunit was secreted but inactive, with no receptor binding or activity measured in vitro, whereas orientation of the b-subunit at the Nterminus of the a-subunit resulted in improved secretion rates and permitted intramolecular interactions similar to the native heterodimer, in addition to comparable in vitro IC  and EC  values ().
These findings with single-chain hCG led to the development of single-chain analogs of LH and FSH [(LHba, LHbDa (in which the terminal  aa of LHb were removed), LHbD-CTP-a, LHb-CTP-a, and FSHb-CTP-a; Table  ], which had comparable or improved in vitro secretion and biological activity comparable with the native heterodimers (, , ). Again, these single-chain analogs were engineered with the b-subunits oriented at the N-terminus of the a-subunit, using the hCGb CTP sequence as a linker. The CTP contains multiple proline and serine residues and is predicted to lack substantial secondary structure, thereby facilitating folding and native intersubunit heterodimer-like interactions. Additionally, the O-linked glycosylation sites of the CTP reduced hepatic clearance rates, contributing to increased serum half-life and increased biopotency of the single-chain analogs. The pharmacokinetic and pharmacodynamic profiles of FSHb-CTP-a have been determined in Rhesus monkeys by SC injection or IV bolus ( IU/kg). The absorption half-life of FSHb-CTP-a was threefold slower than recombinant FSH following SC injection, and the elimination half-life was increased twofold or fourfold over recombinant FSH when administered SC or IV, respectively (). The same study also demonstrated that a single SC dose of the singlechain analog could stimulate estrogen production for  to  days ().
In vivo biopotency of the single-chain analogs of FSHb-CTP-a and hCGba were also tested in sheep passively immunized against GnRH, to suppress endogenous gonadotropin secretion. Concurrent administration of the single-chain analogs ( IU/kg IV), followed by  IU hCG IV after  days to induce ovulation, resulted in elevated serum progesterone and the presence of corpus lutea, highly suggestive of successful ovulation. Neither analog promoted estradiol production in isolation but dual administration resulted in a robust estradiol increase,  days postinjection (), therefore confirming that the singlechain analogs have in vivo biological activity. This study, demonstrating that the analogs could be administered in combination to induce estradiol production and folliculogenesis, led to the development of dual-active, single-chain gonadotropin constructs, including FSHb-CTP-CGb-a, FSHb-CTP-LHb-CTP-a, and CGb-FSHb-CTP-a (Table ) , with both FSHR and LHR activities (, , ). The constructs FSHb-CTP-CGb-a and FSHb-CTP-LHb-CTP-a were administered to sheep using the same experimental design to test the single-chain analogs. Both dual-active constructs elicited increases in serum estradiol concentration,  to  days after administration, similar to that stimulated by dual injection of the two single-chain gonadotropin constructs. In addition, an increase in ovarian weight (attributed to increased numbers of follicles) and the presence of corpus lutea were observed (, ). The clearance rate of the dualactive construct FSHb-CTP-LHb-CTP-a was also significantly improved compared with endogenous ovine gonadotropin ( to  hours) (, ).
Despite these promising indications, to date, singlechain or dual-active gonadotropin analogs remain untested in humans.
Differentially glycosylated gonadotropin analogs
Another strategy used to produce gonadotropins with altered signaling/pharmacokinetic properties was the production of differentially glycosylated analogs. The addition of an N-terminal extension sequence to introduce two additional N-linked glycosylation sites (ANITVNITV) to the glycoprotein a-subunit of FSH was found to increase its half-life, three-to fourfold compared with FSH in a rat model (). This analog (N-a FSH; Table ) exhibited lower in vitro-specific activity than FSH but had higher in vivo potency (measured by ovarian weight and increased estrogen production in rats), likely as a result of its increased half-life. A single dose was as effective as daily doses of the same concentration of FSH ().
Single-chain analogs, which have substitution of the CTP linker with a synthetic linker containing two N-linked carbohydrate signal sequences (N linker), have also been demonstrated to increase serum halflife in rats, with comparable in vitro and in vivo potencies to those of analogs containing the CTP. A single-chain FSH construct with this substitution (FSHb-N-a; Table ) had comparable activity in vitro to recombinant FSH. Its half-life was also similar to FSHb-CTP-a and approximately twofold greater than recombinant FSH in immature female rats after a single IV injection. Rats administered with FSHb-N-a also had higher mean ovarian weights,  days after administration, compared with those administered with recombinant FSH ().
A linker with N-linked glycosylation sites is advantageous, as in contrast to O-linked sites (such as those of the CTP), there is a defined N-linked glycosylation consensus sequence that can be exploited to generate differentially glycosylated hormone variants (). Analogs with varying numbers of N-linked glycosylation sites (FSHb-N-a and FSHb-N-a) between the subunits (Table ) have been produced to determine effects on biological half-life and biopotency. Whereas elimination half-life in female rats was comparable between analogs containing the "To date, single-chain or dualactive gonadotropin analogues remain untested in humans."
N linker (FSHb-N-a) or CTP (FSHb-CTP-a) linkers, there was only a modest improvement in clearance rates for the FSHb-N-a analog (). Interestingly, despite a plateau in elimination half-life and comparable augmentation of ovarian weight following injection of FSHb-CTP-a, FSHb-N-a, and FSHb-N-a analogs, there were increases in the number of antral follicles and substantial increases in inhibin A following treatment with all the N-linked analogs (). The in vivo bioactivities of FSHb-N-a and FSHb-N-a have since been examined further, with -week-old female mice given a single IP injection of  IU of the N-linked analogs, recombinant FSH, or pregnant mare's serum gonadotropin (PMSG; which has activity at both FSHR and LHR in nonequine species). The bioactivities of FSHb-N-a and FSHb-N-a, measured by ovarian and uterine weights, inhibin A production, and a number of antral follicles, superseded the recombinant FSH responses. PMSG performed best in all measured parameters as a result of its activities at both LHR and FSHR. However, the supplementation of the FSHb-N-a and FSHb-N-a injections with daily injections of . IU hCG resulted in responses comparable with that of PMSG (). In another mouse study,  IU IP of FSHb-N-a, FSHb-CTP-a, or PMSG was administered, followed by  IU hCG IP,  hours later. Increased ovulation and embryo maturation were observed with FSHb-N-a when compared with FSHb-CTP-a (. 6 . embryos vs  6  embryos, respectively) (). The delivery rates and litter sizes were comparable between PMSG and FSHb-N-a and were higher or comparable with recombinant FSH treatment ().
Again, although promising in vivo results have been obtained for these differentially glycosylated analogs, they have yet to be developed further for clinical use.
Gonadotropin conjugates and suspensions with increased half-life and bioavailability Alternative methods to try to improve gonadotropin/ glycoprotein hormone pharmacokinetic properties have included attachment of synthetic polymers to increase half-life and bioavailability and therefore, biological activity. Covalent addition of polyethylene glycol (PEG; PEGylation) results in many advantageous properties, such as increased solubility of hydrophobic molecules, increased size (reduced renal clearance), reduced immunogenicity, and protection from proteolytic degradation. Injection of SpragueDawley rats with . mg/kg IM of a recombinant PEGylated TSH analog resulted in a -fold increase in plasma half-life and elevated thyroxine (T) levels for up to  hours, with only moderate effects on receptor binding affinity (). FSH has also been PEGylated via covalent amide linkage (Table ) , and this analog retained FSH activity, as measured by progesterone secretion of cultured bovine cumulus cells (), and also had greater bioavailability compared with the non-PEGylated control in rats ().
Another strategy for increasing FSH half-life was the creation of a fusion-protein consisting of FSH aand b-subunits fused to a binding partner (e.g., immunoglobulin Fc fragments) of the neonatal Fc receptor (FcRn). FSH fusion proteins containing immunoglobulin Fc fragments had increased stability and serum half-life. In addition, these fusion proteins are protected from endosomal degradation by binding to the FcRn, facilitating recycling (-). When female rats were injected SC with  nmol/kg recombinant FSH or a heterodimeric FSH molecule conjugated to an immunoglobulin Fc fragment (FSHFc; Table ), ovarian weight was increased twofold in the FSH-Fc-treated rats when compared with the recombinant FSH-treated group ().
Modification of hormones by conjugation to endogenous molecules, such as FcRn binding partners, may result in advantageous properties, in addition to increased half-life, such as oral/pulmonary bioavailability. For example, fusion proteins comprising FcRn binding partners can be shuttled across epithelial barriers, opening the intriguing possibility of creating a gonadotropin analog that can be administered via nasal or pulmonary routes using aerosols. This has been demonstrated in the cynomolgus monkey, with a single pulmonary dose of heterodimeric FSH-Fc ( mg/kg), eliciting a -fold increase in serum inhibin B levels (). Conjugation of peptidic hormones and large macromolecules to vitamin B has also been shown to confer oral bioavailability. Vitamin B interacts with an intrinsic factor, which in turn, binds to its cognate receptor located on the terminal ileum of the small intestine and is internalized by endocytosis. Vitamin B conjugation to macromolecules, such as gonadotropins with poor oral bioavailability, may therefore improve uptake via oral administration. Whereas this method has not yet been applied to gonadotropins, a D-lys GnRH analog has been successfully crosslinked to monocarboxyl-vitamin B, and this conjugate has been shown to retain bioactivity when administered orally (PO) in a mouse ovulation assay ().
Another approach to increase hormone half-life was the development of sustained-release formulations. Single injections of porcine FSH dissolved in an aluminum hydroxide gel suspension were used to stimulate folliculogenesis in both rabbits and cows (, ). The number of oocytes recovered and the number fertilized following a single injection of the aluminum hydroxide adjuvant were not statistically different than those treated with daily injections of porcine FSH dissolved in saline, and measurement of serum FSH concentrations indicated that the levels of hormone were sustained throughout the treatment period, confirming its sustained release (, ). In rabbits, the aluminum hydroxide gel preparation was compared with one of FSH dissolved in an alternative adjuvant, polyvinylpyrrolidone, but superovulation was found to be much more effective when FSH was administered in the aluminum hydroxide preparation ().
Whereas these modified analogs with improved bioactivity/bioavailability have not been tested clinically, they do offer an exciting possibility for possible future development of improved or less invasive gonadotropin therapeutics.
Polypeptide-gonadotropin antagonists
In addition to the development of polypeptide-based gonadotropin preparations/analogs for activation of the gonadotropin receptors, a number of strategies have also been used in an attempt to generate polypeptide-based gonadotropin antagonists for potential application in contraception. Fusion of two hCG b-subunits as a single chain (hCGbb; Table ) resulted in an analog able to bind to the LHR (albeit with a binding affinity lower than hCG;  and  nM, respectively), which exhibited a dose-dependent inhibition of hCG actions (measured by decreased serum testosterone concentration) in a rat model ().
As a result of the importance of glycosylation for gonadotropin function, it has also been proposed that deglycosylated gonadotropins, which retain receptor binding activity but with reduced bioactivity (see the "Gonadotropin hormone structure and function" section), could also act as competitive antagonists with therapeutic potential (, , , ). Deglycosylation can disrupt dimerization of the gonadotropin subunits, but this can be overcome by the addition of specific dimerization sequences () or by use of single-chain hormones in which the two subunits are covalently joined (see the "Single-chain and dualactivity gonadotropins" section). Indeed, treatment with  IU of a single-chain version of partially deglycosylated hCG (Table ) has been shown to reduce steroid hormone production and ovulation in rats pretreated with  IU PMSG when compared with stimulation with  IU hCG (). In addition, factors associated with OHSS, such as vascular permeability and expression of vascular endothelial growth factor, were reduced in these animals, suggesting that this analog could ameliorate the effects of prolonged exposure to hCG after ovulation has been triggered in patients with a high risk of OHSS (). However, there are conflicting opinions regarding the antagonistic properties of the deglycosylated hormone, with one study showing no decrease in progesterone levels when the deglycosylated hormone was administered to healthy females in the midluteal phase, although the authors acknowledged that this may be a result of the presence of "spare receptors" and the inability to achieve sufficient serum concentrations of the antagonist (). In addition, chemical methods of deglycosylation, such as hydrogen fluoride treatment, often result in incomplete deglycosylation, which may confound the interpretation of data ().
Nonpeptidic Low-Molecular-Weight Gonadotropin Receptor Agonists and Antagonists
Whereas the development of polypeptide gonadotropin analogs with increased serum half-life/bioactivity (described earlier) shows promise of single injections to replace the multiple injections of the natural hormones used in ART, small-molecule/low-molecular-weight (LMW) orally active agonists would avoid trauma of injection and overcome problems of preparation uniformity (arising from posttranslational modification of peptide-based analogs) and have greater compound stability (). However, despite several drugdevelopment programs focused on identification of LMW gonadotropin analogs, only three have entered human trials, and none are commercially available.
Desirable properties of such LMW analogs would include good oral bioavailability, high potency, high specificity, and high lipophilicity (which would enable interaction with allosteric sites within the TM domains of the target receptors; see later).
In addition to application in ART, orally bioavailable, small-molecule antagonists at gonadotropin receptors may have clinical application as novel oral contraceptives with potentially greater specificity and therefore, reduced risk of side-effects, such as headaches, weight gain, nausea, and increased risk of serious complications, such as venous thromboembolism, which occurs with current steroidal contraceptive drugs ().
LMW LHR agonists may also be used potentially for women at risk for OHSS. This syndrome has been linked to fertility treatments using hCG injections to achieve oocyte maturation and ovulation. hCG has a long serum half-life; therefore, LMW LHR agonists with shorter half-lives may well circumvent/attenuate the risk of OHSS. In addition, orally active LMW compounds are more amenable to titrating dosage.
Despite the theoretical, therapeutic potential of LMW modulators of the gonadotropin receptors, a number of persistent problems have hindered their development into clinically applicable drugs. Firstly, the high degree of sequence conservation across the glycoprotein hormone receptor family and other related receptors, such as the LRR containing GPCRs, means that drug crossreactivity can be an obstacle. Indeed, this has been an issue with some LMW analogs. However, as the natural glycoproteins are highly specific, there is no reason to believe that this cannot be achieved with the LMW molecules. Secondly, the glycoprotein hormones are large heterodimeric proteins that interact with their cognate receptors via multiple structurally conserved contact sites and additionally, have a two-step binding and activation "Small molecule/LMW orally active agonists would avoid trauma of injection and overcome problems of preparation uniformity." mechanism (Fig. ) . Therefore, it is difficult to imagine orthosterically binding LMW molecules that could simultaneously occupy and induce the structural changes within the glycoprotein hormone receptor ECDs to attain full efficacy of activation with low potency. However, this concern has been overcome with allosterically binding LMW molecules (see later). Thirdly, promising lead compounds, identified through in vitro screening, have been found to have little/no in vivo efficacy (), as is a common feature of smallmolecule development in the pharmaceutical industry.
GPCRs are amphipathic molecules, complicating crystallization/structural analysis, but exciting advances in X-ray crystallography methodologies, including the use of thermodynamically stabilizing mutations and nanobody-based stabilization of GPCR active states, have revealed new opportunities for novel drug design (, ). One such avenue is that of allosteric modulators of GPCR activity that interact with the receptor at a site distinct from the orthosteric ligand binding site (site of binding of the endogenous ligand). Allosteric GPCR modulators generally fall into three classes: allosteric agonists and positive and negative allosteric modulators (PAMs and NAMs, respectively). Allosteric agonists have agonist activity in the absence of the orthosteric ligand, whereas PAMs and NAMs are defined as molecules that either potentiate or attenuate agonist-mediated responses, respectively. This can be through modulation of orthosteric agonist binding affinity or the ability of the agonist-occupied receptor to interact with intracellular signal transducers. The targeting of allosteric sites can be advantageous, as they are generally less evolutionarily conserved and often contain unique structural features, providing a platform for the development of drugs with a greater degree of target specificity (). Additionally, many allosteric modulators only have activity in the presence of the cobound endogenous ligand, with the advantage that GPCR activation is limited to the spatiotemporal release of the endogenous ligand (). This is especially relevant in the context of many neuroendocrine signaling axes, which have cyclical patterns of hormone release.
Allosteric binding sites for LMW compounds have now been described for a number of GPCRs. Through the modeling of the gonadotropin hormone receptor TM domains, using adenosine A  receptor and rhodopsin receptor molecular models, alongside a number of biochemical assays, and studies using chimeric receptors, it has been proposed that the gonadotropin receptors have two allosteric sites: one major and one minor, labeled P and P, respectively () (Fig. ) . These sites are located toward the ECL half of the TM helices, close to the transition of TMto-ECL domains, with P located among TMs III, IV, V, and VI and P among TMs I, II, III, and VII (). A substantial number of structural scaffolds have been described that can allosterically bind to the gonadotropin receptors, and a number of cell-based screening assays have been used over the last  years, resulting in the identification of various lead compounds/chemical scaffolds, with specific in vitro cellular and in vivo physiological activity profiles.
The most frequently targeted of the glycoprotein hormone receptors for LMW drug discovery is the FSHR. This is perhaps unsurprising, given the multiple injections of hormone necessary for ovarian hyperstimulation in assisted reproductive therapy protocols. However, although a number of promising LMW compounds have been developed for both gonadotropin receptors, none are yet in clinical use. The following sections will describe the development of some of the most promising LMW compound classes that have been identified to date. For more detailed insight regarding the chemical properties of many of these different compound classes, the reader is referred to van Straten and Timmers ().
FSHR agonists
Piperidine carboxyamides
In , Serono (now Merck Serono) used a luciferase reporter gene high-throughput screen to identify piperidine carboxyamide derivatives with activity in Chinese hamster ovary (CHO) cells stably expressing FSHR. A lead compound with an EC  of . nM was identified and was subsequently shown to have poor stimulation of estradiol in rat granulosa cells (EC  . mM). However, this initial finding was valuable in the discovery of a number of chemical scaffolds with improved FSHR agonistic activity ().
Thiazolidinones Thiazolidinone (TZD) scaffolds have been used previously in a number of drug-discovery programs and have excellent drug-like properties (-). Indeed, low-potency FSHR agonists have been described that contain thiazole core structures (). In , Affymax screened ., compounds from a large TZD library for agonist activity at the FSHR using a luciferase reporter gene assay in CHO cells expressing FSHR. The design of this library was based on data that had identified a TZD compound with moderate agonist activity at the FSHR ( to  mM). Several hits with increased potency were identified from this screen, including "compound ," which was a partial agonist (% relative to recombinant FSH stimulation), with an EC  of  nM (). Compound development addressed synthesis issues regarding stereoselectivity on the heterocyclic ring (the less active trans isomer predominates over the desired cis isomer during synthesis) and resulted in stable TZD compounds containing g-lactam congeners and -alkyl substituents with comparable potencies and efficacies to the original lead compound (, ). Another screen by Affymax and Wyeth (since acquired by Pfizer) of a collection of combinatorial libraries containing over , compounds and representing . core scaffolds identified two additional FSHR agonists with TZD scaffolds (with potencies of~ mM) (). Parallel synthesis resulted in three compounds with nanomolar potency. Subsequent studies using chimeric receptors in which the N-terminal domain and TM domains of the TSH receptor (TSHR) and FSHR were interchanged indicated that these analogs act via an interaction with the TM domains of the FSHR (unlike the natural hormone that interacts with the ECD). Further analysis using chimeric receptors narrowed down the site of interaction to the area of the receptor between TM I and ECL (). One of the identified compounds, "compound " (Table ) , was demonstrated to be a full agonist of the FSHR and could induce progesterone production in mouse adrenal Y cells transfected with FSHR and estradiol production in primary rat granulosa cells (), had in vivo activity in a mouse cumulus expansion assay, and demonstrated a dose-dependent increase in the number of ovulated oocytes in a rat ovulation assay. Although this compound had promising FSHR activity, unfortunately, it had poor oral bioavailability, and micronucleus screening assays identified genotoxic effects (-).
Wyeth/Affymax further characterized the pharmacological properties of several TZD compounds and demonstrated that small modifications to the TZD ring can result in completely different pharmacologies, resulting in anything from agonists through to negative modulators able to inhibit estradiol production in rat granulosa cells via activation of Ga i () ( Table ) . Thus, a single TZD core structure has the potential to be used to develop a spectrum of LMW allosteric modulators targeting multiple FSHR signaling pathways. The most potent compounds contained heterocyclic diketopiperazine substituents (). Lead optimization, aimed at modification of the diketopiperazine core side-chains, increased their potency from the low micromolar to the low nanomolar range in both luciferase reporter gene and cAMP assays (). However, these compounds do not appear to have been developed further, and there is no information regarding specificity or in vivo activity of these hit compounds. At a similar time, Serono also filed a patent describing substituted piperazine compounds with FSHR agonistic activity in the low micromolar to low nanomolar range ().
Hexahydroquinolines
Two patents filed in  by Organon detail the use of hexahydroquinoline scaffolds (-phenyl--oxol,,,,,-hexahydroquinolines) as FSHR activators in vitro (, ). These patents describe several LMW compounds with potencies in the low nanomolar (, nM) range in an in vitro luciferase reporter assay. In , the same company published a description of a hexahydroquinoline LMW PAM of the FSHR, Org - (Table ) . This molecule had agonist activity in a luciferase reporter assay and was demonstrated to bind via a site distinct from the endogenous hormone. In addition to the allosteric agonist activity, coincubation with FSH demonstrated Org - PAM activity, inducing a substantial (sixfold) increase in FSH affinity, which translated to a fourfold increase in FSH potency in the luciferase reporter assay (). Org - was also demonstrated to induce follicular growth in a rat ovulation assay when administered PO and thus, represented an orally active FSHR LMW agonist with in vivo efficacy (). MSD has also investigated similar compound scaffolds, including MK- (a dihydropyrroloisoquinoline) as LMW allosteric FSHR agonists. However, when MK- was tested in a dose-escalation study in healthy human females, it was unable to confirm effects on follicular development and found that it unexpectedly affected thyroid function (), suggestive of activity at the TSHR, which emphasizes the importance of good selectivity margins for these compounds.
Other agonists MSD has also described two LMW FSHR agonists with undisclosed scaffolds and interesting pharmacological profiles. These agonists have nanomolar activity at the FSHR ( to  nM) and display similar responses to recombinant FSH in a luciferase reporter assay (). These LMW FSHR agonists were unique in that they had particularly short-acting profiles (half-life . to . hours, time to reach maximum serum concentration . to . hour). Intriguingly these compounds resulted in % suppression of ovulation in cycling Orga rats at doses of  mg/kg PO when administered twice daily. The inhibition of ovulation resulted from the formation of luteinized, unruptured follicles, and this effect was reversible, with spontaneous ovulation recovery following discontinuation of treatment (). These results could not be fully replicated in mono-ovulatory species (cynomolgus monkey) (), but this still represents an approach to the development of a reversible female contraceptive.
FSHR antagonists
Sulfonic acid-containing compounds
The sulfonic acid-containing compound, suramin, has been used as an IV antiparasitic for over  years (). In addition to its antiparasitic properties, suramin has been demonstrated to inhibit the signaling activity of a number of peptide hormones, including platelet-derived growth factor, epidermal growth factor (), and FSH (, ). Subsequently, suramin has been shown to compete with FSH for binding to the FSHR-ECD (). Interestingly, a second mechanism of inhibition may involve disruption of certain GPCR-G protein interactions (, ). In a cohort of male patients receiving suramin as a therapy for refractory cancer, all showed a marked decrease in plasma testosterone, and this effect was mirrored in a rat Leydig cell assay (). The dramatic in vivo effect on testosterone secretion, combined with lack of specificity (including documented LHR interaction) (, ), precipitated the development of other LMW FSHR antagonists containing sulfonic acid moieties (, ). Compound screening by Wyeth identified three (bis) sulfonic acid, (bis)benzamide FSHR antagonists with moderate potencies of cAMP inhibition, estradiol inhibition (granulosa cell assay), and progesterone inhibition (in an adrenal Y cell assay) and IC  values in the low micromolar range (). Unlike suramin, these compounds displayed marked improvement in specificity, with no LHR binding activity measured up to  mM and no inhibition of TSHR cAMP response up to  mM (). Also in , a napthalene sulfonic acid compound ("compound "; Table  ) was identified by Wyeth through library screening for compounds that inhibited FSH binding to FSHR. The lead compound inhibited FSH binding with an IC  of . mM, and interestingly, although it bound the FSHR ECD, the inhibition of FSH binding was noncompetitive and led to a reduction in FSH binding sites but not affinity (). This compound was also able to inhibit the FSH cAMP response in a dose-dependent manner with % efficacy, inhibited estradiol production in granulosa cells, and when administered at  mg/kg IP to cycling female rats, inhibited ovulation in % of treated animals (). Analogs were developed to examine structure-activity relationships, and a number of substitutions were identified as critical for activity, including the sulfonic acid moiety (). Issues regarding off-target effects, safety, and oral bioavailability have hampered the development of these compounds for clinical application. In the in vivo rat ovulation model, napthalene sulfonic acid induced mild inflammation of the ovarian surface epithelium, and the rats displayed a substantial retardation in growth rate (). It is unclear whether these effects may have indirectly contributed to ovulation inhibition. Furthermore, the oral absorption of the (bis)sulfonic acid, (bis)benzamide compounds was predicted to be poor, and the conversion of the sulfonic acid moieties to carboxylic acid, although predicted to improve absorption, abolished FSHR binding activity ().
Aminoalkylamides A substituted aminoalkylamide series of FSHR antagonists has also been reported with a spectrum of potencies. Two of the most potent compounds, identified in a cAMP screening assay by Ortho-McNeil Pharmaceutical, were tested for ovulation and spermatogenic inhibitory effects in Wistar rats, but following oral dosing at  mg/kg, only very limited effects were noted (). In the absence of any pharmacokinetic data, it is unclear whether the limited effects are a result of restricted oral bioavailability/poor intestinal absorption/rapid clearance, as the two compounds had activity in in vitro cAMP and granulosa cell assays.
Tetrahydroquinolines
Organon identified a tetrahydroquinoline (THQ) scaffold with FSHR agonistic activity in a luciferase assay screen, with a moderate potency of . mM and an efficacy of % relative to FSH. This compound was selected for lead optimization, and surprisingly, it was discovered that introduction of an aromatic group at position  of the THQ scaffold resulted in a switch from full agonist to full antagonist, with nanomolar IC  values (compound ; Table ) (). Biphenyl moieties were also tolerated, implying that the binding pocket was large and lipophilic, with competition binding assays determining that the pocket is likely to be located in the TM domain (). In a mouse ex vivo follicular growth assay, one THQ compound with a biphenyl substituent was demonstrated to inhibit follicular growth in the presence of FSH and inhibited ovulation in % of follicles ().
Benzamide derivatives
An homogenous time-resolved fluorescence screening assay was used by Addex Pharmaceuticals to identify FSHR NAMs and identified a benzamide compound (ADX; Table ) with NAM activity (IC  . mM with % inhibition of FSH EC  ). This NAM was ascertained to be a biased antagonist of the FSHR, as in the presence of FSH, it inhibited cAMP and progesterone production in vitro in a dose-dependent manner but failed to inhibit estradiol production and at doses . mM, stimulated estradiol production (). This finding was surprising and challenges the paradigm that estradiol production is entirely dependent on cAMP signaling. In an in vivo setting, SC administration of ADX at  mg/kg resulted in no differences in number of oocytes recovered and ovarian weight of rats treated with  mg pituitary FSH and ovulated with  IU hCG (). The authors of this earlier article postulate that this may be a result of the inability of ADX to suppress estradiol production. However, women with PCOS have successful pregnancies despite suppression of estradiol with letrozole or tamoxifen, so suppression of estradiol may be necessary but not sufficient. Two additional benzamide analogs were subsequently identified by Addex, corroborating the description of biased antagonism identified for ADX and further substantiating the requirement for blockade of both arms of the FSHR steroidogenic signaling pathway to inhibit follicular maturation and ovulation in rats ().
Other FSHR antagonists
Pyrrolobenzodiazepine and acyltryptophanol LMW FSHR antagonists were identified through luciferase and homogenous time-resolved fluorescence screening assays, respectively, with IC  concentrations in the micro-and nanomolar ranges (, ).
LHR agonists
A number of LHR agonists have been developed by the pharmaceutical industry.
Thienopyrimidines
Organon reported an orally active, nonpeptidic LMW agonist for the LHR. In a high-throughput screen of a compound library, using a luciferase reporter gene assay, a thieno[,-d]pyrimidine was identified as having agonist activity at the LHR (). A series of thienopyrimidine and thienopyridine analogs were subsequently synthesized and their in vitro activity determined. The most potent LHR agonist identified was the thienopyrimidine, Org  (EC  of  nM) (), which was found to stimulate testosterone production in cultured mouse Leydig cells (EC  of . mM) and was able to stimulate ovulation in % of urinary FSH-primed female mice, using a dose of  mg/kg PO (). Org  has since been shown to have partial agonist activity at the TSHR but with -fold lower potency and no substantial activity at the FSHR (, ). With the use of computer-based docking, a binding pocket was delineated among TMs III, IV, V, VI, and VII and ECL, with the cleft formed in the LHR larger than that of TSHR (, ). This pocket was verified through mutagenesis of receptor residues predicted to be of importance for Org  interaction and by synthesis of analogs hypothesized to increase specificity or ablate binding. Of particular importance is a glutamate residue in TMIII that is conserved between LHR and TSHR and is predicted to form a hydrogen bond with the amino group of Org  (, ). Mutation of this residue completely ablated Org -mediated TSHR signaling. Furthermore, an analog of Org  with addition of "steric bulk" to the amide (an extra methyl group) was sufficient to block Org -mediated TSHR signaling but not LHR signaling, resulting in a substantial improvement in specificity. This steric bulk was hypothesized to inhibit insertion into the smaller TSHR binding cleft but still allow accommodation into the slightly larger LHR pocket (, ).
Further lead optimization of Org  led to the development of another thienopyrimidine, Org  (Table ) , which displayed nanomolar potency at the LHR (EC  of . nM; % efficacy compared with LH), no activity at the TSHR, and reduced activity at the FSHR (-fold reduced potency than at the LHR) (). Interestingly, this study also highlighted biased signaling properties of Org . Whereas LH activation of the LHR stimulated both cAMP (EC   pM) and phospholipase C (PLC; EC  . nM), no substantial activation of the PLC pathway by Org  was measured, suggestive of biased agonism (). In addition, whereas Org  did not antagonize LH-induced intracellular cAMP accumulation, it did strongly antagonize (% maximal inhibition) the LH-induced activation of PLC in a noncompetitive manner, suggestive of an allosteric binding mechanism (). In support of this, Org  was shown to reduce noncompetitively [  I]hCG binding (). Subsequent studies have both confirmed and repudiated the described increase in [
 I]hCG dissociation (, ), but nonetheless, the observed inability of the LMW compounds to compete with hormone binding supports the theory that these compounds are acting in an allosteric manner.
The biological activity of Org  has since been investigated more thoroughly. In an ex vivo ovulationinduction assay using cultured mouse follicles,  mM Org  was able to stimulate maximal levels of ovulation and progesterone production, similar to that seen using hCG, and was able to induce testosterone production in primary Leydig cell cultures with high potency, although with lower efficacy than hCG (). In vivo, Org  has been shown to have good oral availability (% in rat and % in dog) with a short half-life (. hours in rat and . hours in dog) (). The occurrence of OHSS has been associated with the long half-life of hCG (half-life~ to  hours depending on source and purification methodology) (); therefore, the short half-life of Org  may have appreciable advantages. Indeed, when Org  was administered to PMSG-primed female rats, even at high concentrations ( mg/kg), there was no evidence of an increase in vascular permeability or vascular endothelial growth factor levels, unlike that seen with hCG or LH ().
In GnRH antagonist-treated rats, a single -mg/kg dose of Org  PO resulted in ovulation of a normal number of ova, comparable with the hCG control ( IU/kg SC). Ova fertilization rate, implantation rate, and subsequent fetal development were all within normal parameters. In male rats at concentrations $ mg/kg PO, similar levels of testosterone stimulation were measured to those produced after treatment with  IU hCG SC ().
Perhaps most promisingly, Org  and another related thienopyrimidine, Org , have shown efficacy in humans. Both were shown to induce ovulation when administered PO in a preclinical trial with healthy females. Org  was safe and well "Issues regarding off-target effects, safety, and oral bioavailability have hampered the development of these compounds." tolerated up to a maximum dose of  mg (). The GnRH analog, Ganirelix, was administered SC for pituitary suppression in conjunction with recombinant FSH to stimulate follicular growth. Administration of  mg Org  resulted in ovulation induction in .% of patients, as determined by transvaginal ultrasound and a midluteal rise in progesterone ().
Org  has activity at the FSHR, in addition to the LHR, and this lack of selectivity could be an issue for clinical use. However, it has been shown that ligand dimerization can aid in subtype selectivity for structurally similar GPCRs. Dimeric compounds, in which two Org  moieties were joined with flexible ethylene glycol linkers, or rigid benzene core spacers have been synthesized and evaluated (). Both series of compounds had increased LHR selectivity (two-to fivefold) compared with Org  alone in a luciferase reporter gene assay, either as a result of reduced potency (rigid linkers) or reduced efficacy (flexible linkers) at the FSHR ().
Pyrazoles
In , screening of a compound library by a group at Merck Serono identified pyrazoles as another class of LMW compounds with activity at the LHR (). From the results of the initial screen, a focused pyrazole library was developed, and the activity of compounds within the library was assessed using a cAMP-specific scintillation proximity assay in CHO cells stably expressing human LHR. A compound termed "compound " (Table ) displayed the best potency (EC  of  nM) and efficacy (% of LH response) (). Compound  was able to stimulate testosterone production in cultured rat Leydig cells and elicit a robust increase in serum testosterone in testosteronesuppressed -month-old male rats treated with  mg/ kg compound  IP (). No oral bioavailability or bioactivity of this compound has yet been reported. Interestingly, compound  was not able to compete with hCG in LHR radioligand binding assays, suggesting that it also interacts with the receptor at an allosteric site (). A structure-activity relationship study determined the allosteric pocket to be large and lipophilic (similar to the THQ series), as polar groups were not tolerated as substituents of the pyrazole ring nitrogen, providing further evidence of localization of the allosteric site within the receptor TM domain ().
LHR antagonists
Terphenyls
In an effort to identify other allosteric LHR modulators, radiolabeled Org  was used to screen for novel LMW ligands in a kinetic radioligand binding assay. A number of hit compounds were identified that increased the dissociation rate of Analogs with dual-receptor activity The high degree of sequence conservation among the glycoprotein hormone receptors frequently translates as a loss of selectivity during glycoprotein hormone receptor LMW compound development. One strategy used to circumvent this is the creation of bivalent ligands combining combinations of LMW agonists and antagonists via linkers to increase specificity of responses (-). In a study that combined an Org -based LMW LHR agonist (which also has FSHR activity) with a very selective LMW FSHR antagonist based on the THQ compound  ( Table ) using an ethylene glycol spacer, a promising series of analogs was developed, which exhibited activity at the LHR (albeit with reduced potency) but no detectable FSHR activity (). The in vivo activities of these bivalent compounds have yet to be examined.
Conclusions and Future Perspectives
Gonadotropins from natural and recombinant sources have been the mainstay of infertility treatment in men and women for over eight decades and remain a crucial component of induction of ovulation for assisted reproduction, thus satisfying the needs of patients with infertility worldwide. Nevertheless, there remain considerable challenges to develop less invasive approaches to minimize multiple injection protocols, reduce the risk of OHSS, and improve outcomes for conditions, such as PCOS. The development of an impressive suite of molecules, including fused b-subunits, hybrid LH-FSH molecules, differentially glycosylated gonadotropins, polypeptide LH and FSH antagonists, longer-acting analogs, and sustained release formulations has considerable potential, but their full development and use have yet to be thoroughly explored. A contributing factor to this is the acquisition of the companies developing these innovative drugs by large pharma and subsequent abandonment of the development programs. Despite this huge endeavor and creativity in producing a wide range of novel polypeptide gonadotropin analogs, the only commercial products arising from the gonadotropin analog developments are recombinant gonadotropins and corifollitropin alfa. Moreover, these recombinant FSH and LH preparations can still be subject to differential glycosylation with resulting variation in biological activity. Whereas the recombinant gonadotropins have advantages of greater batch-to-batch consistency and purity compared with hMG and hCG, the latter are still widely used, as they are less expensive and effective.
Good progress has been made in development of LMW orally active LHR and FSHR agonists and antagonists, and three have been evaluated in clinical studies. The allosteric LHR agonists Org  and Org  displayed excellent bioavailability, safety, and pharmacokinetic and pharmacodynamic properties, and both demonstrated good efficacy in induction of ovulation protocols. Therefore, these compounds appear to fulfill the major criteria required for LMW gonadotropin analogs (e.g., specificity, oral bioavailability, good efficacy). However, evolving priorities of the pharmaceutical companies running these programs have meant that further clinical development of these compounds has been halted.
As multiple injections of FSH are required for oocyte recruitment, LMW orally active FSH agonists would be desirable substitutes. An LMW FSHR allosteric agonist (MK-; MSD), developed from a class of compounds that had promising activity in rat models, had no effect on follicular development or estradiol production but an effect on thyroid function (). Thus, further research is required to produce efficacious orally active FSHR LMW agonists as substitutes for multiple injections of conventional polypeptide FSH with high specificity.
The observation that MK- has thyroid activity serves to highlight the importance of good-selectivity margins for these LMW compounds, which has been a limiting factor for the development of many of these analogs. Although peptide analog preparations with mixed LHR/FSHR activity have been/are used clinically (e.g., hMG), "pure" analogs with activity at only one receptor are preferred, as this enables design of personalized treatment regimens. In addition, differing potencies of "mixed activity" LMW analogs at the different receptors may have implications for the design/efficacy of clinical protocols.
As mentioned previously regarding polypeptide gonadotropin molecules, another major stumbling block to the realization of these exciting possibilities for novel therapeutics has been the acquisition of reproductive health companies by big pharma and the termination of gonadotropin analog development in view of different priorities of the acquiring companies. The acquisitions of Organon and Schering halted the promising LHR allosteric agonist program. Likewise, the acquisition of Wyeth by Pfizer may have halted development of the FSHR agonist. Encouragingly, a number of small biotech companies (e.g., Addex Therapeutics and TocopheRx) have taken up the baton, and we may yet see LMW analogs enter the clinic for a diversity of applications.
One exciting developing area of drug discovery is in the arena of allosteric modulators, which can modulate the effects of exogenous or endogenous ligands, either positively (PAMs) or negatively (NAMs). These compounds offer subtle advantages over traditional agonist and antagonist ligands, such as improved specificity and thus, reduced side-effects. Therefore, development of PAMs/NAMs that target the gonadotropin receptors would be an exciting development in this field and is one currently being pursued by companies, such as Addex Therapeutics.
Another exciting development in the arena of LMW gonadotropin analogs is their ability to restore function to inactivating mutations in human gonadotropin receptors. Not only have LMW LHR allosteric agonists been shown to act as pharmacological chaperones and restore cell-surface expression of intracellularly retained mutant LHRs () (an outcome of the majority of inactivating point mutations in the LHR) (), but also, function of binding-deficient and signaling-deficient mutants can be restored (). As there is no current treatment for these patients, the small molecules potentially offer a breakthrough in personalized and precision medicine in reproduction, with broader implications for treating a wide spectrum of diseases arising from inactivating mutations in GPCRs.
In addition to the application of gonadotropin analogs as regulators of reproduction, agonists and antagonists of upstream regulators of GnRH (kisspeptin and neurokinin B) are emerging as subtle and precise regulators of gonadotropin secretion (-). These show promise of more closely simulating normal physiology as a result of their more proximal position in the axis regulating GnRH. For example, kisspeptin has been shown to be effective in a more gentle induction of ovulation, which may reduce the risk of OHSS (). Therefore, these upstream regulators may have substantial application as surrogates for gonadotropin therapies. The near-normal FSH and low LH in patients with inactivating mutations of neurokinin B or its receptor () suggested that neurokinin B antagonists may be able to reverse the high LH-to-FSH ratio, characteristic of PCOS, and this has now been demonstrated (). As hot flashes coincide with LH pulses, the slowing of LH pulses with neurokinin B antagonists would potentially ameliorate the condition, which has has now been shown (-).
Future roles and novel applications of gonadotropins targeting extragonadal tissues are emerging and may herald a new era of gonadotropin therapeutics. Postmenopausal women have low estrogens, elevated FSH, concomitant bone loss, and increased body fat, suggesting that FSH, as well as low estrogens, may be playing a role. In an ovariectomized mouse model, an antibody to FSHb was found to robustly inhibit bone resorption and stimulate bone synthesis (). In another study, the antibody was shown to induce thermogenic adipose tissue and reduce body fat (). There is now substantial literature on the subject, which is beyond the scope of this review. The reader is therefore referred to comprehensive reviews "Future roles and novel applications of gonadotropins targeting extragonadal tissues are emerging." on this subject (, ). Despite an increasing body of evidence supporting a role for FSH in bone and fat regulation, there are contradictory findings in both human and rodent studies, and robust conclusions are difficult to tease out in view of the relation of estrogen to FSH and the often-opposed effects of the two hormones, such as on osteoclasts ().
Elevated LH may also exert neurodegenerative effects, such as those seen in Alzheimer's disease (, ). Additionally, increased FSH and FSHR expression in prostatic cancers and a controversial role for FSH/FSHR in ovarian cancer (-) open up an even wider spectrum of potential novel applications for LH and FSH agonists and antagonists.
Although these observations are compelling, the extent of gonadotropin receptor expression in extragonadal tissues and the effects of gonadotropins on diverse tissues remain to be fully explored, using a range of experimental approaches and advanced epidemiological studies. Therefore, it remains to be seen whether gonadotropin analogs may have use in these applications.
